Aptose Biosciences holds $4.1 million in cash as of March 31, 2026, insufficient to fund operations without external advances.
Aptose Biosciences Inc. posted a GAAP loss of $2.99 per share, reflecting ongoing financial strain. The company’s total cash and restricted cash stood at $4.1 million as of March 31, 2026, raising liquidity concerns.
The biotech firm relies on advances from Hanmi to sustain operations, as current cash reserves are inadequate. Cost-reduction efforts are underway to extend its cash runway amid limited financial flexibility.
No immediate market reaction was disclosed in the release.